Quantum-Si Secures $50 Million Funding for Advancements in Proteomics Technology

Quantum-Si Secures Funding for Proteomics Advancements

Quantum-Si Incorporated, recognized as The Protein Sequencing Company™, announces a substantial securities purchase agreement with institutional investors. This registered direct offering involves the sale of 15,625,000 shares of common stock priced at $3.20 per share, anticipated to generate approximately $50 million in gross proceeds before expenses. The closing of this offering is expected around January 6, 2025, pending customary closing conditions. The funds raised will play a crucial role in bolstering the company’s working capital and supporting general corporate purposes.

This funding initiative highlights Quantum-Si's strategic focus on advancing its pioneering technologies in the field of proteomics. The company is committed to enhancing its innovative Platinum® instrument, which is designed to support Next-Gen Protein Sequencing™. By securing these funds, Quantum-Si reinforces its position as a leader in the proteomics market, facilitating research capabilities in various critical areas including drug discovery and diagnostics. The investment is not only a financial maneuver but a strategic step towards revolutionizing protein sequencing technology, ultimately aiming to improve outcomes in healthcare and life sciences.

Quantum-Si’s ongoing efforts reflect a broader trend in the biotech sector, where funding is vital for driving innovation and staying competitive. The company emphasizes the importance of transparency by urging stakeholders to consider forward-looking statements cautiously, as actual results may differ from projections. This initiative marks a significant milestone in Quantum-Si's journey, as it seeks to transform the landscape of protein analysis and contribute meaningfully to scientific advancements.

In addition to the funding announcement, Quantum-Si engages its stakeholders by providing access to offering documentation, including a final prospectus supplement, available on the SEC's website and through A.G.P./Alliance Global Partners, the sole placement agent for this offering. The company remains dedicated to enhancing its outreach, inviting stakeholders to connect through its website and social media platforms for further updates on its innovative endeavors in the proteomics field.